In-DOTA-TCO-trastuzumab

Phase 1Monoclonal antibody

RRadboud University Medical Center

In-DOTA-TCO-trastuzumab is one of 15 small molecule programs targeting HER2 Positive. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HER2 PositiveRecruiting

HER2 PositivePhase 1

Recruiting

Competition

Competitive Landscape

17 competitors in HER2 Positive

#DrugCompanyPhaseTrials

Herceptin

OOrganon and Co

Phase 3

8 2

Taxol

Teva

Phase 2

3 3

Zaniducla

Jazz Pharmaceuticals

Phase 2

2 4

Eloxatin

Teva

Phase 2

2 5

Gemzar

Johnson & Johnson

Phase 2

1 6

Beyfortus

BeiGene

Phase 2

1 7

Abraxane

Bristol-Myers Squibb

Phase 2

1 8

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

3 9

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

1 10

Perjeta

Roche

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

HER2 Positive

NCT07009184

Clinical

Trials by Indication[1]

HER2 Positive1 trial

TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers, a Phase 0/I Study.

Recruiting·RRadboud University Medical Center·Phase 1·NCT07009184·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for In-DOTA-TCO-trastuzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — In-DOTA-TCO-trastuzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for In-DOTA-TCO-trastuzumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Radboud University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 1[1]
Company: RRadboud University Medical Center

In-DOTA-TCO-trastuzumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

HER2 Positive1 trial

References

Drug Info

Quick Facts

Related News